ZNTL Ingmar Bruns sells $7K worth of shares
Feb 11, 2026, 5:37 AM
0.00%
What does ZNTL do
Zentalis Pharmaceuticals, a San Diego-based clinical-stage biopharmaceutical company, develops novel small molecule therapeutics for cancer, including WEE1 inhibitor azenosertib and BCL-2 inhibitor ZN-d5. The company went public on April 3, 2020, and employs 168 people.
Ingmar Bruns sold 2,962 shares of ZNTL on 6 February at $2.43 per share, worth a total of $7K. They now own 33,667 ZNTL shares, or a 8% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.